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SUPPLEMENTARY APPENDIX
Online Supplementary Figure S1 . Methylation Specific PCR and pyrosequencing. (A) Methylation-specific PCR was carried out to assess RUNX1 proximal promoter methylation using specific RUNX1 promoter primers for methylation and unmethylation (MF: 5'-TTCGGGTTGCGTATAGTAGC; MR: 5'-ATAAAC-CCGACCGAAAAAAT; UMF: 5'-GTTTGGGTTGTGTATAGTAGT; UMR: 5'-TATAAACCCAACCAAAAAAAT). For methylation-specific PCR reaction, we included universal methylated DNA (CpGenome Universal Methylated DNA, Millipore, Temecula, CA, USA) as positive control, and normal blood DNA as negative control. Quality controls for bisulphite conversion were performed for each reaction. (B) The second methylathion analysis of the RUNX1 proximal promoter was realized by bisulphite genomic pyrosequencing of the corresponding six CpG islands located within the fragment amplified by MSP. Following sodium bisulphite treatment, the specific region was PCR amplified using specific primers for modified DNA (Forward: 5'-GGTTAGTATGTAGGTTTGGATG and Reverse: 5'-CTATAAATAAAAATACCTAAAAATAAAC) and PCR products were sequenced. The positive control also corresponds to the universal methylated DNA. In both analyses we included DNA from CD34 + and CD34 -cells isolated from cord blood, AND2 human embryonic stem cell line, AML Kasumi1 cell line, the studied case and DNA from the patient in remission. No methylation within the RUNX1 proximal promoter was observed in any of these cases. We conclude that this epigenetic mechanism is not involved in the inactivation of the remaining gene copy in the patient.
